ada standards of care 2025 obesity pharmacotherapy glp-1 Framework for the pharmacological treatment and its complications from the European Association for the Study of Obesity (EASO) ada standards of care 2025

It does not mean the medication is toxic or dangerous. However, you should always discuss any side effects with your medical provider to ensure your dosage is appropriate

In several comparative trials, Tirzepatide outperformed many traditional antidiabetic agents as well as some established GLP-1 receptor agonists

Insulin resistance, visceral adiposity, gut permeability, and metabolic endotoxemia create a baseline inflammatory state that lowers the threshold for autoimmune flares

Still, researchers continue to study the long-term safety of these medications

Gastrointestinal Tolerability Over Time GI symptomsespecially nausea, vomiting, and constipationare among the most common complaints in GLP1 therapy